Bristol-Myers Squibb on Thursday cut its guidance for 2017, saying it now expects adjusted earnings of $2.70 to $2.90 a share for the year, down from its previous guidance of $2.85 to $3.05. In the fourth quarter, the drugmaker posted earnings of $894 million, or 53 cents a share, compared with a loss of $197 million, or a loss of 12 cents, a year earlier.
Category: Bristol Myers Squibb
Bristol-Myers Falls Further Behind Merck in Lung Cancer Race
Bristol-Myers Squibb Co. fell after the drugmaker said it wouldn’t seek accelerated approval for a combination of its drugs to treat first-line lung cancer.
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
Years before becoming a top cancer specialist, Eric Winer used to save money on his own medical care by talking U.S. pharmacists into giving him expired treatments for free. Winer, who has a bleeding disorder known as hemophilia, knew the drugs would still work for a brief time after the official use-by date.
The Scariest Thing About Bristol-Myers Squibb’s Dividend
With a current yield of 2.67%, investors still have reason to show the love. But there is something that might seem scary to some investors — the company’s ability to keep the dividends flowing at current levels.
Ono Pharma’s Wild 2016 Ride Cuts Stock Valuation by $16 Billion
Having surged as much as 34 percent as of mid-April, the stock finished the year down more than 41 percent, marking its worst performance in more than 50 years. The swing reduced its market capitalization by about 1.87 trillion yen from a record high in April.